Methods for the treatment of alzheimers disease and compositions therefore

A method to treat, prevent or ameliorate pathological conditions associated with Aβ secretion comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of one or more modulators of any one or more proteins selected from the group consisting of those disclosed in Table 1.

A method to identify modulators useful to treat, prevent or ameliorate pathological conditions associated with Aβ secretion comprising assaying for the ability of a candidate modulator to inhibit the activity of a protein selected from the group consisting of those disclosed in Table 1.

A method to identify modulators useful to treat, prevent or ameliorate pathological conditions associated with Aβ secretion comprising assaying for the ability of a candidate modulator to inhibit gene expression of a protein selected from the group consisting of those disclosed on Table 1.

A pharmaceutical composition comprising one or more modulators of any one or more proteins selected from the group consisting of those disclosed in Table 1 in an amount effective to treat or ameliorate pathological conditions associated with Aβ secretion in a subject in need thereof.

A method to diagnose subjects suffering from pathological conditions associated with Aβ secretion who may be suitable candidates for treatment with one or more modulators of any one or more proteins selected from the group consisting of those disclosed in Table 1 comprising assaying mRNA levels of said protein in a biological sample from said subject wherein a subject with increased mRNA levels compared to controls would be a suitable candidate for modulator treatment.

A method to treat, prevent or ameliorate pathological conditions associated with Aβ secretion comprising

• (a) assaying a subject for mRNA levels for any one or more proteins selected from the group consisting of those disclosed in Table 1;
• and,
• (b) administering to a subject with increased levels of mRNA compared to controls a modulator of any one or more of said proteins in an amount sufficient to treat or ameliorate said pathological conditions.

A method to treat, prevent or ameliorate pathological conditions associated with Aβ secretion comprising:

• (a) assaying a subject for protein levels of any one or more proteins selected from the group consisting of those disclosed in Table 1;
• and,
• (b) administering to a subject with increased protein levels compared to controls a modulator of any one or more of said proteins in an amount sufficient to treat or ameliorate said pathological conditions.